Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lawrence Einhorn, M.D.
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Siteman Cancer Center
St Louis, Missouri, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- Musc Hollings Cancer Center
Charleston, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2013
- Primary completion
- 31 Mar 2015
- Completion
- 30 Jun 2015
- Last update posted
- 25 May 2016
- Registered enrollment
- 65
- Registry id
- NCT01736917
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.